Nothing Special   »   [go: up one dir, main page]

WO2008112317A3 - Triol form of rosuvastatin - Google Patents

Triol form of rosuvastatin Download PDF

Info

Publication number
WO2008112317A3
WO2008112317A3 PCT/US2008/003470 US2008003470W WO2008112317A3 WO 2008112317 A3 WO2008112317 A3 WO 2008112317A3 US 2008003470 W US2008003470 W US 2008003470W WO 2008112317 A3 WO2008112317 A3 WO 2008112317A3
Authority
WO
WIPO (PCT)
Prior art keywords
rosuvastatin
triol form
triol
analysis
reference standard
Prior art date
Application number
PCT/US2008/003470
Other languages
French (fr)
Other versions
WO2008112317A2 (en
Inventor
Valerie Niddam-Hildesheim
Anna Balanov
Irena Veinberg
Original Assignee
Teva Pharma
Valerie Niddam-Hildesheim
Anna Balanov
Irena Veinberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma, Valerie Niddam-Hildesheim, Anna Balanov, Irena Veinberg filed Critical Teva Pharma
Priority to BRPI0803085-5A priority Critical patent/BRPI0803085A2/en
Priority to EP08726880A priority patent/EP2121631A2/en
Priority to MX2008014552A priority patent/MX2008014552A/en
Priority to CA2680604A priority patent/CA2680604C/en
Priority to JP2009504512A priority patent/JP5330225B2/en
Publication of WO2008112317A2 publication Critical patent/WO2008112317A2/en
Publication of WO2008112317A3 publication Critical patent/WO2008112317A3/en
Priority to IL200449A priority patent/IL200449A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Provided is a rosuvastatin triol and its use as a reference standard for analysis of rosuvastatin. (I)
PCT/US2008/003470 2007-03-13 2008-03-13 Triol form of rosuvastatin WO2008112317A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
BRPI0803085-5A BRPI0803085A2 (en) 2007-03-13 2008-03-13 rosuvastatin triol form
EP08726880A EP2121631A2 (en) 2007-03-13 2008-03-13 Triol form of rosuvastatin
MX2008014552A MX2008014552A (en) 2007-03-13 2008-03-13 Triol form of rosuvastatin.
CA2680604A CA2680604C (en) 2007-03-13 2008-03-13 Triol form of rosuvastatin
JP2009504512A JP5330225B2 (en) 2007-03-13 2008-03-13 Triol rosuvastatin
IL200449A IL200449A0 (en) 2007-03-13 2009-08-18 Triol form of rosuvastatin

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US90691407P 2007-03-13 2007-03-13
US60/906,914 2007-03-13
US91846607P 2007-03-15 2007-03-15
US60/918,466 2007-03-15

Publications (2)

Publication Number Publication Date
WO2008112317A2 WO2008112317A2 (en) 2008-09-18
WO2008112317A3 true WO2008112317A3 (en) 2008-11-06

Family

ID=39650560

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/003470 WO2008112317A2 (en) 2007-03-13 2008-03-13 Triol form of rosuvastatin

Country Status (8)

Country Link
EP (1) EP2121631A2 (en)
JP (1) JP5330225B2 (en)
KR (1) KR100945760B1 (en)
BR (1) BRPI0803085A2 (en)
CA (1) CA2680604C (en)
IL (1) IL200449A0 (en)
MX (1) MX2008014552A (en)
WO (1) WO2008112317A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2576518B1 (en) * 2010-06-07 2016-08-10 Pharmathen S.A. Improved process for the preparation of propenal intermediate and derivatives thereof
CN112782333B (en) * 2020-12-25 2022-07-12 石家庄四药有限公司 HPLC detection method for pitavastatin isopropyl tert-butyl ester diastereoisomer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005056534A1 (en) * 2003-12-02 2005-06-23 Teva Pharmaceutical Industries Ltd. Reference standard for characterization of rosuvastatin

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005056534A1 (en) * 2003-12-02 2005-06-23 Teva Pharmaceutical Industries Ltd. Reference standard for characterization of rosuvastatin

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HULL C K ET AL: "Quantification of rosuvastatin in human plasma by automated solid-phase extraction using tandem mass spectrometric detection", JOURNAL OF CHROMATOGRAPHY B: BIOMEDICAL SCIENCES & APPLICATIONS, ELSEVIER, AMSTERDAM, NL, vol. 772, no. 2, 5 June 2002 (2002-06-05), pages 219 - 228, XP004352369, ISSN: 1570-0232 *

Also Published As

Publication number Publication date
MX2008014552A (en) 2009-03-09
CA2680604C (en) 2012-08-07
BRPI0803085A2 (en) 2011-08-30
JP2009519353A (en) 2009-05-14
EP2121631A2 (en) 2009-11-25
CA2680604A1 (en) 2008-09-18
KR100945760B1 (en) 2010-03-08
WO2008112317A2 (en) 2008-09-18
IL200449A0 (en) 2010-04-29
KR20090010195A (en) 2009-01-29
JP5330225B2 (en) 2013-10-30

Similar Documents

Publication Publication Date Title
AU2009276339A8 (en) Pyrimidine compounds, compositions and methods of use
WO2008039359A3 (en) Bicyclic pyrimidine kinase inhibitors
ZA200800120B (en) Reactive distillation for the dehydration of mixed alcohols
WO2007090881A3 (en) Modified release formulation
WO2008039499A3 (en) Production of isoprenoids and isoprenoid precursors
IL197668A0 (en) Rna antagonist compounds for the modulation of pcsk9
WO2007115821A3 (en) Organic compounds
EP2266056A4 (en) Dynamic formulas for spreadsheet cells
WO2011133504A3 (en) Nanozymes, methods of making nanozymes, and methods of using nanozymes
WO2008058118A3 (en) Preparation of montelukast and its salts
IL200375A0 (en) Remedy for chemotherapy-resistant cancer containing hla class-i-recognizing antibody as the active ingredient and use of the same
WO2005105079A3 (en) Novel imidazoles
WO2010025370A3 (en) Preparation of ranolazine
EP2118174B8 (en) Use of tocopherol
WO2009085176A3 (en) Use of tetramic acid derivatives for controlling nematodes
AU2009213453A8 (en) Anti-ADAM-15 antibodies and utilization of the same
WO2008112317A3 (en) Triol form of rosuvastatin
MX2007004427A (en) Crystalline rosuvastatin intermediate.
AU2009254959A8 (en) Processes for the synthesis of levocetirizine and intermediates for use therein
WO2010028004A3 (en) Substituted berbines and processes for their synthesis
AU2009249106A8 (en) Arylsulfonamide compounds, compositions and methods of use
AU2007271980A8 (en) Use of Fosfluridine Tidoxil (FT) for the treatment of intraepithelial proliferative diseases
AU2006907075A0 (en) Compounds and Methods of Use
AU2014216020B9 (en) Heterocyclic compound and use thereof
AU2005906584A0 (en) Use of Inhibitors of Prolyl-4-Hydroxylases

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880008162.2

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2009504512

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2008726880

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08726880

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: MX/A/2008/014552

Country of ref document: MX

Ref document number: 1020087027688

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 4791/DELNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 200449

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2680604

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: PI0803085

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20081112